NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders

Restricted access

REMS are a particularly important issue for oncology and the National Comprehensive Cancer Network (NCCN). A disproportionate number of drugs with complex REMS are used in patients with cancer or hematologic disorders. REMS policies and processes within oncology may act as a model for other clinical areas. A breadth of experience and access to a wide knowledge base exists within oncology that will ensure appropriate development and consideration of the practical implications of REMS. NCCN is uniquely positioned to assume a leadership role in this process given its status as the arbiter of high-quality cancer care based on its world-leading institutions and clinicians. Notwithstanding the potential benefits, the successful design, implementation, and analysis of the FDA's recent requirement for REMS for some high-risk drugs and biologics will present significant challenges for stakeholders, including patients, providers, cancer centers, manufacturers, payors, health information technology vendors, and regulatory agencies. To provide guidance to these stakeholders regarding REMS challenges, the NCCN assembled a work group comprised of thought leaders from NCCN Member Institutions and other outside experts. The Work Group identified challenges across the REMS spectrum, including the areas of standardization, development and assessment of REMS programs, medication guides, provider knowledge and impact on prescribing, provider burden and compensation, and incorporation of REMS into clinical practice.

The NCCN Oncology REMS Work Group was convened in order to advise stakeholders regarding recommendations related to REMS design, implementation, and assessment. The content of this article represents the work of NCCN and may not necessarily reflect the opinions of the external Work Group members or the organizations with which they are affiliated.

Correspondence: Edward C. Li, PharmD, BCOP, National Comprehensive Cancer Network, 275 Commerce Drive, Suite 300, Fort Washington, PA 19034. E-mail:li@nccn.org
  • 1

    U.S. Food and Drug Administration. Guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf. Accessed January 4, 2010.

    • Search Google Scholar
    • Export Citation
  • 2

    Identification of drug and biological products deemed to have risk evaluation and mitigation strategies for purposes of the Food and Drug Administration Amendments Act of 2007. Washington, DC: U.S. Department of Health and Human Services. Fed Regist 2008;73(60):1631316314.

    • Search Google Scholar
    • Export Citation
  • 3

    U.S. Food and Drug Administration. Opioid Drugs and Risk Evaluation and Mitigation Strategies (REMS). Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm. Accessed January 5, 2010.

    • Search Google Scholar
    • Export Citation
  • 4

    U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting; Reopening of Comment Period. Washington, DC: U.S. Department of Health and Human Services. Fed Regist 2009;74:53509–53510.

    • Search Google Scholar
    • Export Citation
  • 5

    Food and Drug Administration Amendments Act of 2007. Pub L No. 110-85, 21 USC 301 Stat 930. Available at: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110_cong_public_laws&docid=f:publ085.110. Accessed August 10, 2010.

    • Search Google Scholar
    • Export Citation
  • 6

    Enzi MB, Kennedy EM. Risk management and intrusions on medical practice: striking a balance. Health Aff (Millwood) 2007;26:678680.

  • 7

    Weingart SN, Brown E, Bach PB. NCCN Task Force Report: Oral Chemotherapy. J Natl Compr Canc Netw 2008;6(Suppl 3):S114

  • 8

    U.S. Food and Drug Administration. Approved Risk Evaluation and Mitigation Strategies (REMS). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Accessed June 1, 2010.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 394 350 22
PDF Downloads 43 40 3
EPUB Downloads 0 0 0